Anzeige
Meldung des Tages: $95 Silber explodiert – Prince Silver vor dem nächsten Durchbruch!!

Evogene Aktie News

Aktie
WKN:  A0Q7UP ISIN:  IL0011050551 US-Symbol:  EVGN Branche:  Biotechnologie Land:  Israel
1,03 $
+0,00 $
0,00%
0,8765 € 22.01.26
Depot/Watchlist
Marktkapitalisierung *
4,43 Mio. €
Streubesitz
97,15%
KGV
-
Index-Zuordnung
-

Evogene News

07.01.26 - PR Newswire
Evogene and Unravel Biosciences Announce Collaboration to Develop a First-in-Class Therapy to Reverse Neurological Damage in Demyelinating Disorders
Evogene and Unravel Biosciences Announce Collaboration to Develop a First-​in-Class Therapy to Reverse Neurological Damage in Demyelinating Disorders PR Newswire
30.12.25 - PR Newswire
Evogene Announces Appointment of Dr. Olga Nissan as its Vice President of Business Development
Evogene Announces Appointment of Dr. Olga Nissan as its Vice President of Business Development PR Newswire
20.11.25 - PR Newswire
Evogene Reports Third Quarter 2025 Financial Results
Evogene Reports Third Quarter 2025 Financial Results PR Newswire
11.11.25 - PR Newswire
Casterra and Fantini Partner to Advance Agricultural Mechanization for Scalable Commercial Castor Farming
Casterra and Fantini Partner to Advance Agricultural Mechanization for Scalable Commercial Castor Farming PR Newswire
06.11.25 - PR Newswire
Evogene Schedules Third Quarter 2025 Financial Results Release
Evogene Schedules Third Quarter 2025 Financial Results Release PR Newswire
28.08.25 - PR Newswire
Evogene to Present at H.C. Wainwright 27th Annual Global Investment Conference in New York
Evogene to Present at H.C. Wainwright 27th Annual Global Investment Conference in New York PR Newswire
19.08.25 - PR Newswire
Evogene Reports Second Quarter 2025 Financial Results
Evogene Reports Second Quarter 2025 Financial Results PR Newswire
12.08.25 - PR Newswire
Evogene and Professor Ehud Gazit of Tel Aviv University Announce a Collaboration to Develop New Therapeutics for Metabolic Diseases
Evogene and Professor Ehud Gazit of Tel Aviv University Announce a Collaboration to Develop New Therapeutics for Metabolic Diseases PR Newswire
29.07.25 - PR Newswire
Evogene Schedules Second Quarter 2025 Financial Results Release
Evogene Schedules Second Quarter 2025 Financial Results Release PR Newswire
08.07.25 - PR Newswire
Evogene Announces Completion of Transaction for the Sale of Lavie Bio's Activity to ICL
Evogene Announces Completion of Transaction for the Sale of Lavie Bio's Activity to ICL PR Newswire
10.06.25 - PR Newswire
Evogene Announces Completion of First-In-Class Foundation Model for Generative Molecule Design, Developed in Collaboration with Google Cloud
Evogene Announces Completion of First-​In-Class Foundation Model for Generative Molecule Design, Developed in Collaboration with Google Cloud PR Newswire
21.05.25 - PR Newswire
Evogene Reports First Quarter 2025 Financial Results
Evogene Reports First Quarter 2025 Financial Results PR Newswire
08.05.25 - PR Newswire
Evogene Schedules First Quarter 2025 Financial Results Release
Evogene Schedules First Quarter 2025 Financial Results Release PR Newswire
23.04.25 - PR Newswire
Canadian Investment Regulatory Organization Trade Resumption - EVGN
Canadian Investment Regulatory Organization Trade Resumption - EVGN Canada NewsWire
23.04.25 - PR Newswire
Canadian Investment Regulatory Organization Trading Halt - EVGN
Canadian Investment Regulatory Organization Trading Halt - EVGN Canada NewsWire
21.04.25 - PR Newswire
ICL to Acquire the Activity of Evogene's Subsidiary, Lavie Bio
ICL to Acquire the Activity of Evogene's Subsidiary, Lavie Bio PR Newswire
06.03.25 - PR Newswire
Evogene Reports Fourth Quarter and Full Year 2024 Financial Results
Evogene Reports Fourth Quarter and Full Year 2024 Financial Results PR Newswire
06.03.25 - PR Newswire
Evogene Announces the Appointment of Nir Nimrodi as the New Chairperson of the Board, Effective March 5, 2025
Evogene Announces the Appointment of Nir Nimrodi as the New Chairperson of the Board, Effective March 5, 2025 PR Newswire
20.02.25 - PR Newswire
Evogene Schedules Fourth Quarter 2024 Financial Results Release
Evogene Schedules Fourth Quarter 2024 Financial Results Release PR Newswire
13.02.25 - PR Newswire
AgPlenus Announces Discovery of a New Mode of Action for Fungicides Against Wheat Disease
AgPlenus Announces Discovery of a New Mode of Action for Fungicides Against Wheat Disease PR Newswire

Newssuche

Videos

newspaper
22.01.26 -33,33%
Trading Insights vom 22.01.26
Preisschock bei Erdgas! Was sind die Gründe, wie geht man damit um? Gold auf neuem Allzeithoch: wie ... Mehr »